Lung cancer · curated MDI catalog

Molecular tests for lung cancer

Molecular testing in lung cancer can serve different purposes, including treatment profiling, diagnostic support, screening and monitoring. Tests should be compared only within the clinical purpose and population for which they were studied.

20 curated profiles currently match this page. MDI lists them alphabetically and does not rank tests by isolated performance numbers, evidence counts, price or popularity.

  • CanCatch Custom — Tumor-informed personalized ctDNA MRD approach using WES baseline profiling and patient-specific mutation tracking.
  • Cancerguard — Multi-cancer early detection laboratory-developed test for adults 50–84; breast/prostate screening and precancer detection are outside the documented current use.
  • cobas EGFR Mutation Test v2 — FDA-approved real-time PCR EGFR companion diagnostic for NSCLC.
  • EPISEEK — Blood-based multi-cancer early detection LDT analyzing abnormal DNA methylation signals associated with more than 60 cancer types.
  • FirstLook Lung — Blood-based cfDNA fragmentomics laboratory-developed test used as an adjunct in the lung-cancer screening pathway; not a replacement for LDCT.
  • Galleri — Prescription-only multi-cancer early detection test.
  • Guardant Reveal — Tissue-free ctDNA MRD/recurrence and therapy-response monitoring test with current methylation-focused commercial lineage.
  • Invitae Personalized Cancer Monitoring — Tumor-informed personalized ctDNA monitoring assay for solid tumors.
  • LucenceINSIGHT — Prescription blood-based multi-cancer early detection family using ctDNA and viral DNA with machine-learning tissue localization.
  • MyRisk — Germline hereditary-cancer panel; current documented configuration contains 63 clinically recommended genes and must not inherit analytical metrics from historical 25-gene validation.
  • NeXT Personal Dx — Tumor-informed personalized ctDNA LDT using WGS-derived patient-specific signatures for MRD, recurrence and treatment-response monitoring.
  • Nodify CDT — Blood autoantibody classifier that raises malignancy risk for selected pulmonary nodules.
  • Nodify XL2 — Blood-based proteomic classifier to identify lung nodules likely benign.
  • Oncomine Dx Target Test — FDA-approved targeted NGS oncology companion diagnostic platform.
  • OneTest for Cancer — Blood-based multi-cancer early detection LDT combining multiple serum tumor biomarkers with a machine-learning risk algorithm.
  • OverC Multi-Cancer Detection — Blood-based cfDNA methylation multi-cancer early detection test with six-cancer current product scope; jurisdiction-specific regulatory status.
  • ProVue Lung — Proteomics-based blood LDT designed to complement LDCT lung-cancer screening in high-risk adults.
  • SimpleScreen Lung — Blood-based multiomic LDT intended to increase lung-cancer screening participation among eligible high-risk adults not completing LDCT.
  • SPOT-MAS 10 — Blood-based multi-cancer screening test using cfDNA methylation and fragmentomic signals with machine learning.
  • Tempus xF+ — 523-gene plasma liquid-biopsy comprehensive genomic profiling assay for therapy selection and molecular profiling in advanced cancer.

How to interpret these records

Clinical purpose comes first. Historical evidence remains attached to the assay version that was actually studied. Evidence counts describe curation coverage, not test quality. Commercial availability is separate from authorization, reimbursement, eligibility and appropriate use.

Find all tests · Understand the evidence · Methodology & provenance